Copyright
©The Author(s) 2018.
World J Gastroenterol. Apr 7, 2018; 24(13): 1478-1485
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1478
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1478
Figure 1 Treatment regimen of sofosbuvir and ribavirin.
SOF: Sofosbuvir; RBV: Ribavirin; EOT: End of treatment.
- Citation: Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485
- URL: https://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i13.1478